13 Jan 05
Morgan Levy (formally E-Focus Resourcing) has pleasure in announcing that we have re-branded to Morgan Levy with effect from January 2005.
GARY M BRITNELL
04 Jan 05
The development of dendritic cell vaccines to fight cancer is an attractive therapeutic approach. Usually this strategy involves pre-pulsing dendritic cells with cancer antigen and maturing them ex vivo prior to administering them to patients. Limitations to this approach include the cumbersome nature of antigen loading and maturation and the limited immunogenicity of the cells. The company BioVEX have successfully developed viruses to load dendritic cells with antigen. Researchers from Baylor h
20 Dec 04
The outlook for hepatocellular carcinoma (HCC) sufferers is bleak - current medication has a five-year survival rate for those with liver cancer of less than 5% in the developed world and even lower in developing countries. However, patients in trials of a new drug called Sorafenib have seen their survival times double. Datamonitor's Dr Lorna Fern investigates...
14 Dec 04
Britainâ€™s hospital patients, led by Claire Rayner, today called for healthcare professionals to get behind the UKâ€™s first ever Clean Hospitals Summit, planned for April 14-15, 2005.
Anna Harris/ Alan Murray
13 Dec 04
This report introduces the emerging field of oncolytic viruses and the various benefits that oncolytic virology can offer in the treatment of cancer. Clinical data suggest that oncolytic viruses may offer therapeutic advantages over existing cancer therapies such as chemotherapy and radiation and may even act synergistically with these conventional approaches. This report evaluates preclinical and clinical data on oncolytic viruses that have entered the clinic.
10 Dec 04
The recent announcement by the FDA's associate director for science and medicine that sales of GlaxoSmithKline's asthma drug Serevent should be restricted, or halted, led to an estimated 3.8% fall in the company's share price. However, Datamonitor's Laura Harris comments that, with Seretide accounting for the majority of GSK's asthma sales, the panic may be premature.
08 Dec 04
At a recent hearing into the Vioxx affair, the FDA's Dr David Graham named five drugs that he considers too dangerous to be on the market. However, in his testimony, Dr Graham also cited Sanofi-Aventis' Arava as a drug he has recommended be withdrawn. Unlike the other five drugs, Arava has largely escaped the media spotlight, but there may yet be some tough questions asked about its safety.
29 Nov 04
Unique intelligence from eyeforpharma: 'Barriers, best practices and measuring ROI for patient compliance programmes'
26 Nov 04
Study data presented at a major recent conference has demonstrated that Wyeth's novel antibacterial tigecycline acts against drug-resistant pathogens in some serious bacterial infections, including MRSA. While Wyeth will have to work hard to establish tigecycline in this competitive area, its encouraging tolerability profile could give it a useful advantage over existing treatments.
19 Nov 04
Influenza is a global disease which imposes a huge medical and economic burden inevery country of the world. The UK is no exception with one caveat - the virus is probably monitored and tracked more in the UK than any other country around the globe. Over the years, GPs have played a leading role in estimating the quantitative impact of influenza. This started with the pioneering work of William Pickles in the Wensleydale villages and continued with Edgar Hope-Simpson in Cirencester.
17 Nov 04
School can be a difficult place at the best of times, however for the 20 million plus children in the seven major pharmaceutical markets that suffer from attention deficit and hyperactivity disorder (ADHD), it can be especially troubling. This exacerbated by the fact that many patients aren't receiving the best available treatment, according to new research from Datamonitor.
09 Nov 04
Over the past 30 years, numerous clinical trials evaluating a variety of different classes of drugs have conclusively shown the benefit of blood pressure reduction in reducing the risk of strokes and cardiovascular mortality. Moreover, such trials have clearly demonstrated that blood pressure is unlikely to be controlled with a single drug and often two or more therapies are required to achieve blood pressure targets.
05 Nov 04
Altana has announced the delay of its US application for Daxas until late 2005 due to clinical trial enrolment taking longer than originally anticipated. The news will be of further concern to the company's investors, coming on the back of the recent announcement that another of its respiratory drugs, Alvesco, failed to win full FDA approval.
04 Nov 04
Prostate cancer is the most common male malignancy in Western countries. Surgery and radiological procedures for localized prostate cancer offer the possibility for curative treatment. Prostate cancer also represents one of the most lucrative oncology indications for the pharmaceutical industry because drug-based treatment is often very effective at delaying disease progression, even in advanced disease, which encourages high-volume and long-term usage. The use of hormonal manipulation for advan
29 Oct 04
Hepatocellular carcinoma is the fifth commonest cancer worldwide with about one million new cases diagnosed annually. It is estimated that the incidence of hepatocellular carcinoma in the seven major pharma markets will continue to rise over the next decade. There is no gold standard therapy - the market is characterized by high levels of unmet need, large patient potential and high commercial potential. To mark the publication of its new feature "Hepatocellular Carcinoma" LeadDiscovery's analys
22 Oct 04
Treatment with combined estrogen/progestin doubles the risk of VTE in post-menopausal women and for obese women the risk is even higher, a recent study showed. However millions of women no longer taking HRT remain at risk of osteoporosis, which presents a huge market opportunity for non-hormonal classes in treating and preventing osteoporosis.
22 Oct 04
Limitations in the ability to optimize dose modification within the clinical trial setting represents a serious bottleneck in the drug development process. This barrier increases development time, causes the unnecessary early termination of valuable candidates and adds up to $300 million/drug in costs. Petra Biotek are set to knock down these barriers through their computer-based Cycle Dose Modification system. The positive impact that this technology is expected to have on the clinical developm
15 Oct 04
Peripheral arterial disease (PAD), caused by systemic atherosclerosis, is vastly underappreciated despite its abysmal mortality rates. With 5 and 10-year rates of 30% and 50% respectively mortality due to PAD is greater than that caused by coronary artery disease and stroke and is exceeded only by colorectal cancer. Better use of the pharmacological and interventional treatments available would dramatically improve the lives of the millions of PAD patients while at the same time ballooning the r
15 Oct 04
Recruitment is a very inexact science â€“ the statistics in favour of making the right decision based on the traditional interview alone are horrifyingly low (the percentage is in single figures). This is a fact that has really only been acknowledged in recent years and, as a result, organisations have looked for ways to improve the success rate of their selection choices.
14 Oct 04
The recent government suspension of the manufacturing license for major flu vaccine maker Chiron in the UK has left many countries facing a severe shortage in flu vaccine supply for the 2004-05 season. In the light of previous vaccine provision difficulties, Datamonitor's Laura Harris argues that, in the longer term, cell culture vaccines could resolve the annual flu vaccine quandary...
11 Oct 04
Last week, Merck & Co sent shockwaves through the pharmaceutical market with the announcement that it had voluntarily withdrawn its blockbuster arthritis drug Vioxx. Datamonitor's Adele Schulz examines the likely impact of this event, for the remainder of 2004 and beyond, on both Merck and its rivals...
07 Oct 04
The demographics of HIV patients are shifting, with the average age of those infected with HIV ever increasing due to longer life expectancy and higher survival rates. However, with increasingly complex infections and drug resistance developing in long term patients, novel medications and new combinations are now being launched to continue the fight...
05 Oct 04
Renal cell carcinoma (RCC) is a niche cancer that accounts for 2-3% of all solid tumors in the major pharmaceutical markets. Approximately 30,000 patients are diagnosed with the disease each year in the US and 12,000 patients die of the disease annually. The market is currently dominated by the cytokines, but there is significant interest among physicians in the potential of anti-angiogenics, particularly so since renal cell carcinomas are known to be well vascularized. Bayer's BAY 43-9006 is a
01 Oct 04
As the dust settles on Merck's withdrawal of Vioxx's, LeadDiscovery investigates the impact that this will have on the treatment of pain, R&D activity directed towards the identification of new approaches, and on pharmaceutical sales relating to COX-2 inhibitors and related drug classes
30 Sep 04
The market for Alzheimer's therapy is expected to grow from 16 million patients to 21 million by 2010 in the seven major pharmaceutical markets. Alzheimer's disease market in the seven major markets is worth $4.7 billion and will increase to $6.1 billion by the year 2005 and $ 7.8 billion by the year 2010. The major unmet need in this market is for disease modification and disease prevention. Recent findings by British researchers showing that targeting the neuronal adaptor protein X11beta can r
29 Sep 04
The pharmaceutical market for the treatment of neurodegenerative disorders will grow by an unprecedented amount over the next ten years. The aging of the baby-boom generation, combined with new and improved treatments for neurodegenerative disorders such as Alzheimer's and Parkinson's disease will lead to an expansion of the already $30 billion neurodegenerative market. Despite the growth of generic products, Parkinson's disease drug revenues grew an impressive 17% across the seven major markets
22 Sep 04
Earlier this year data was reported that Sankyo's angiotensin II receptor blocker (ARB) olmesartan medoxomil may offer improved anti-hypertensive activity when compared to other therapeutic agents within this highly competitive $31 billion market. More recently clinical data has appeared that shows olmesartan to have additional anti- inflammatory activity in hypertensive patients with vascular inflammation. This may confer additional therapeutic benefit since inflammation is an etiological compo
21 Sep 04
The recent success of monoclonal antibody therapies such as Genentech's Rituxan and Johnson & Johnson's Remicade are driving further development of this field. MAb therapies brought in revenues of over $5.1 billion in 2003, a figure which should nearly triple over the next five years as new MAbs are launched and following the approval of new indications for MAbs already on the market. By 2008, MAbs should account for 32 percent of all revenue in the biotech market. One therapeutic antibody indic
21 Sep 04
It has been estimated that 9% of the US population suffers from moderate to severe non-cancer-related pain. Acute pain resulting from conditions such as headache, muscle spasms, dental problems or following surgery, affects 90 million Americans every year and the development of analgesics represents a major pharmaceutical objective. A recent study has demonstrated the analgesic activity of corticotropin-releasing-hormone (CRH) and has shown that this activity is probably due to activity within t